retatrutide clinical trial status retatrutide Dosing Schedule: Proven 2026 Guide Reta clinical trial data &

[80] The trial reported cumulative occurrence of major adverse cardiovascular events, a primary end-point event of the trial, for 569 of the 8803 patients in the semaglutide group, which were 6.5% of the participants, and for 701 of the 8801 patients in the placebo group, which were 8% of the participants, showing relative 18.8% less major adverse cardiovascular events, such as death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, occurring for participants who had received semaglutide in the trial relative to those who had received placebo over the course of around 48 months, or 34.213.7 months, which was the mean (SD) total duration of the participants in either group's exposure to the placebo or semaglutide during the trial

By combining GLP-1 treatment with personalized lifestyle guidance, we help you achieve results that go far beyond the number on the scale

Real-world dosing scenarios decoded Theory is helpful

A free consultation can clarify your timeline and ensure you dont miss your window

They are prescription medicines, and whether any specific medicine is appropriate is a clinical decision made by a practitioner during an assessment